logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Drugs

Results

Drugs

October 2021

Elranatamab for treating relapsed /refractory multiple myeloma

Elranatamab is in clinical development for relapsed/refractory multiple myeloma (MM). MM is a rare, incurable cancer of the blood that develops from plasma cells in the bone marrow (the spongy tissue inside the inner part of some bones) where large amounts of abnormal plasma cells are produced and interfere with the production of red and …

Drugs

October 2021

Pralsetinib for treating thyroid cancer

Pralsetinib is in clinical development for the treatment of thyroid cancer. Thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck that produces hormones. Thyroid cancer can happen when there are genetic changes in the thyroid cells, which cause them to grow uncontrollably …

Drugs

October 2021

Tislelizumab for advanced non-small cell lung cancer after platinum based chemotherapy

Tislelizumab is in clinical development to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously been treated with platinum-based chemotherapy. NSCLC makes up the majority of lung cancers in the UK. Metastatic NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to …

Drugs

October 2021

Tislelizumab for oesophageal cancer – second line

Tislelizumab is being developed for patients with recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy. Advanced or metastatic ESCC begins in the food pipe and spreads to other parts of the body. Symptoms include difficulty swallowing, persistent indigestion or heartburn, weight loss, pain in the throat, and chronic cough. …

Drugs

October 2021

Bentracimab for reversal of the antiplatelet activity of ticagrelor

Bentracimab is in clinical development for reversal of the antiplatelet activity of ticagrelor. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The risk of blood clots is higher in people who have had a heart attack or chest pain, and are often prescribed ticagrelor alongside aspirin. Ticagrelor …

Drugs

October 2021

Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line

Durvalumab in combination with gemcitabine plus cisplatin is being developed for patients with advanced biliary tract cancer (BTC). BTC is a rare type of cancer that affects bile ducts, which are tubes that link the gallbladder, liver and pancreas together. Bile is produced in the gallbladder and is transported to the small intestine to aid …

Drugs

October 2021

Pembrolizumab in combination with olaparib as maintenance therapy for non-small-cell lung cancer following first line treatment

Pembrolizumab in combination with olaparib is currently in development as a maintenance treatment of non-small cell lung cancer (NSCLC) in those that have not progressed following first line treatment. NSCLC makes up the majority of lung cancers in the UK and most patients are diagnosed at the advanced/metastatic stage where curative treatment with surgery is …

Drugs

October 2021

Tislelizumab in combination with chemotherapy for nasopharyngeal cancer – first line

Tislelizumab in combination with gemcitabine and cisplatin is in clinical development for the treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). NPC is a rare type of cancer that affects the part of the throat connecting the back of the nose to the back of the mouth (the pharynx). It is often difficult …

Drugs

October 2021

Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer

Sacituzumab govitecan is in clinical development for the treatment of adult patients with hormone receptor positive and human epidermal growth factor 2 negative (HR+/HER2-) metastatic breast cancer, whose disease has progressed despite treatment with at least two prior rounds of chemotherapy. Survival outcomes for patients with metastatic breast cancer are poor and current chemotherapy options …

Drugs

October 2021

Fidanacogene elaparvovec for haemophilia B

Fidanacogene elaparvovec in development for the treatment of moderately severe or severe haemophilia B in adult males. Haemophilia B is a hereditary bleeding disorder that results in the blood taking longer to clot than normal. The disorder is caused by having a faulty version of the F9 gene. The F9 gene provides instructions for making …

Get Alerts